Sovaldi is one of the more anticipated oral agents available to treat certain types of HCV infection, in some cases without the need for co-administration of interferon. Unlike other recently available agents which have failed to meet the anticipated benefit, the drug may be combined with an all oral regimen and early signs indicate a low pill burden with lesser adverse effects.